Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
A message from Hikma CEO Riad Mishlawi
Latest stories
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results 22 February 2024
- Hikma completes Xellia acquisition Press Release, Corporate 10 September 2024 Hikma completes Xellia acquisition
- Hikma launches Clindamycin in 5% Dextrose Injection in the US Press Release, Product 03 September 2024 Hikma launches Clindamycin in 5% Dextrose Injection in the US
- Bringing Better Health Within Reach: Improving access to medicine as the partner of choice in MENA Insight, Corporate 28 August 2024 Bringing Better Health Within Reach: Improving access to medicine as the partner of choice in MENA
- Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day Press Release, Product 20 August 2024 Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day
